Lumida
/GRAL
⌘K
Grail Inc

Grail Inc

GRAL
$76.23USD-1.71%-1.33 today

MARKET CAP

3.4B

P/E (TTM)

FWD P/E

DAY RANGE

$76 – $79

52W RANGE

$35
$119

AI Summary

Stalk
StalkMedium

GRAL remains in a Stage 2 advancing uptrend with higher highs & higher lows intact above the rising 50-day and 200-day SMAs. A Bullish Exhaustion signal at recent highs signals weakening upside momentum, and price is currently retracing into the 9-day and 20-day EMAs. A pullback into the 20-day EMA / 50-day SMA support zone offers a tactical entry, but execution is deferred pending acceptance around these levels.

  • Q2’26 revenue $44.7M (+26% YoY); Galleri tests rose 35% to 61K
  • Galleri FDA advisory panel set for Sep 23 2026, boosting market access prospects
  • Q2’26 net loss $110.2M on sustained cash burn, raising funding needs
Full analysis →
STATEMENT·Income statement
USD · GAAP
METRICFY 2024FY 2025TREND
Sales, Adj.$125.6M$147.2M
YoY %+17.2%
P / Sales4.5x21.4x
EV / Sales6.6x22.0x
Gross Profit, Adj.$55.9M$71.3M
YoY %+27.7%
Margin %44.5%48.5%
EV / Gross Profit14.9x45.4x
EBITDA, Adj.$-610.2M$-377.8M
YoY %+38.1%
Margin %-485.8%-256.7%
EV / EBITDA-1.4x-8.6x
EBIT$-2.2B$-562.2M
YoY %+74.3%
Margin %-1743.0%-382.0%
EV / EBIT-0.4x-5.8x
Net Income$-2.0B$-408.4M
YoY %+79.9%
Net Margin-1613.9%-277.5%
EPS (GAAP)-$63.54-$11.11
YoY %+82.5%